A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

NCT07198087 ↗

Phase 1 Completed 40 enrolled Ono Pharmaceutical Co., Ltd.

Non-randomizedParallel-groupOpen-labelOther

Summary

A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants

Timeline

Start: 2025-10-01
Primary completion: 2026-04-09
Completion: 2026-04-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirabrutinib	Small molecule	80 mg	Oral

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Summary

Timeline

Drugs

Indications